OM-174 | 171092-39-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: OM-174
• 英文别名: 2-deoxy-6-O-[2-deoxy-4-O-(dihydroxyphosphoryl)-2-[(R)-3-dodecanoyloxytetradecanoylamino]-β-D-glucopyranosyl]-2-[(R)-3-hydroxytetradecanoylamino]-α-D-glucopyranosyl dihydrogenophosphate；Triacyl lipid A OM-174；[(3R)-1-[[(2R,3R,4R,5S,6R)-2-[[(2R,3S,4R,5R,6R)-3,4-dihydroxy-5-[[(3R)-3-hydroxytetradecanoyl]amino]-6-phosphonooxyoxan-2-yl]methoxy]-4-hydroxy-6-(hydroxymethyl)-5-phosphonooxyoxan-3-yl]amino]-1-oxotetradecan-3-yl] dodecanoate
• CAS: 171092-39-0
• 化学式: C₅₂H₁₀₀N₂O₂₀P₂
• 分子量: 1135.31
• InChiKey: GOWLTLODGKPXMN-MWJFIXGVSA-N

物化性质

• 密度：
  1.25±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  8.6
• 重原子数：
  76
• 可旋转键数：
  46
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  347
• 氢给体数：
  11
• 氢受体数：
  20

反应信息

• 作为产物：
  描述：

  3,4-di-O-benzyl-6-O-{3,6-di-O-benzyl-4-O-(dibenzyloxyphosphoryl)-2-deoxy-2-[(R)-3-dodecanoyloxytetradecanoylamino]-β-D-glucopyranosyl}-2-[(R)-3-benzyloxytetradecanoylamino]-2-deoxy-α-D-glucopyranosyldibenzyloxyphosphate 在 5% Pd(II)/C(eggshell) 氢气 作用下， 以 四氢呋喃 为溶剂， 20.0 ℃ 、600.01 kPa 条件下， 反应 17.0h， 生成 OM-174
  参考文献：
  名称：

  Functionalized Beta 1,6 Glucosamine Disaccharides and Process for Their Preparation

  摘要：

  本发明涉及一种新型化学合成β-(1->6)-连接的葡萄糖胺二糖的方法，该方法涉及与该过程相关的化合物。根据进一步的方面，本发明涉及包含这些化合物的组合物以及这些化合物在二糖和药物合成中的应用。

  公开号：

  US20100168054A1

文献信息

• Adjuvant
  申请人：Catchpole Ian Richard

  公开号：US20110045027A1

  公开（公告）日：2011-02-24

  The present invention provides a novel adjuvant for polynucleotide vaccines, and in particular the present invention provides immunogenic compositions comprising a polynucleotide encoding an antigen capable of eliciting an immune response and an adjuvant comprising an immunostimulatory quantity of a gemini surfactant, or a derivative thereof.

  本发明提供了一种新型的辅助剂，用于多核苷酸疫苗，特别是本发明提供了包含编码能够引起免疫反应的抗原的多核苷酸和包含免疫刺激量的双子星表面活性剂或其衍生物的辅助剂的免疫原性组合物。
• Vaccine compositions comprising virosomes and a saponin adjuvant
  申请人：GlaxoSmithKline Biologicals S.A.

  公开号：EP2269638A2

  公开（公告）日：2011-01-05

  The invention provides virosome preparations from an enveloped virus, in particular from influenza virus, containing an antigen from said virus, and a saponin adjuvant. In particular the invention provides a virosome preparation from influenza virus containing an influenza antigen a QS21, optionally with a sterol. The invention also provides vaccine compositions containing said virosome preparations, methods of preparing said virosome preparations and vaccine containing them.

  本发明提供了包膜病毒（尤其是流感病毒）的病毒体制剂，其中含有所述病毒的抗原和皂素佐剂。本发明尤其提供了一种来自流感病毒的病毒体制剂，其中含有流感抗原 QS21，并可选择使用固醇。本发明还提供了含有所述病毒体制剂的疫苗组合物、制备所述病毒体制剂的方法以及含有所述病毒体制剂的疫苗。
• Novel composition
  申请人：GlaxoSmithKline Biologicals S.A.

  公开号：EP2397153A1

  公开（公告）日：2011-12-21

  The present invention relates to influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to multivalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from at least two influenza virus strains, at least one strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant.

  本发明涉及流感疫苗制剂和免疫流感疾病的疫苗接种方案、它们在医学中的用途，特别是它们在增强对各种抗原的免疫反应方面的用途，以及制备方法。特别是，本发明涉及多价流感免疫原组合物，该组合物包含至少两种流感病毒毒株的流感抗原或其抗原制剂，其中至少一种毒株与大流行爆发有关或有可能与大流行爆发有关，并与水包油乳剂佐剂结合使用。
• Vaccine comprising an oil in water emulsion adjuvant
  申请人：GlaxoSmithKline Biologicals S.A.

  公开号：EP2433648A2

  公开（公告）日：2012-03-28

  The present invention provides an immunogenic composition comprising an antigen or antigen composition and an adjuvant composition comprising an oil in water emulsion, wherein said oil in water emulsion comprises 0.5 - 10 mg metabolisable oil, 0.5 - 11 mg tocol and 0.1 - 4 mg emulsifying agent, per human dose.

  本发明提供了一种免疫原组合物，该组合物包括抗原或抗原组合物和由水包油乳剂组成的佐剂组合物，其中所述水包油乳剂按人剂量计算包括 0.5 - 10 毫克可代谢油、0.5 - 11 毫克托可乐和 0.1 - 4 毫克乳化剂。
• Immunogenic composition
  申请人：GlaxoSmithKline Biologicals S.A.

  公开号：EP2476434A1

  公开（公告）日：2012-07-18

  The present application relates to immunogenic compositions comprising Type 5 and/or 8 capular polysaccharide or oligosaccharide from S. aureus having between 30-100% O-acetylation. Vaccines, methods of treatment using and processes to make an immunogenic composition comprising Type 5 and/or 8 capsular polysaccharides with 30-100% O-acetylation are also described.

  本申请涉及由金黄色葡萄球菌的5型和/或8型荚膜多糖或寡糖组成的免疫原组合物，其O-乙酰化程度在30-100%之间。本申请还描述了疫苗、治疗方法和免疫原组合物的制作过程，这些组合物包含O-乙酰化程度在30-100%之间的5型和/或8型荚膜多糖。